- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04823195
Development Cellular Models of the Ear and Nose to Study the Mechanisms of Hearing (CMAG)
September 15, 2023 updated by: University Hospital, Brest
Development of Cellular Models of the Ear and Nose From Patient Samples to Study the Mechanisms of Hearing
Development of cells culturesissued from Nose and Ear to study auditory mecanisms.
Study of the cis-Modulation of the gene GJB2 for the patients with early presbycusis to identify the genetic cause of hearing loss.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rémi Marianowski
- Phone Number: 02-98-22-33-78
- Email: remi.marianowski@chu-brest.fr
Study Locations
-
-
-
Brest, France, 29609
- Recruiting
- CHRU de Brest
-
Contact:
- Rémi Marianowsk
- Email: remi.marianowski@chu-brest.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
over 18 years old full consent With exostosis, or having cochlear implant surgery, or early presbycusis
Description
Inclusion Criteria:
- Hearing loss Presbycusis Exostosis
Exclusion Criteria:
- Genetic hearing loss
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
GJB2 cis regulation
Time Frame: 2 years
|
Culture cell model
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 15, 2021
Primary Completion (Estimated)
June 15, 2024
Study Completion (Estimated)
June 15, 2024
Study Registration Dates
First Submitted
March 29, 2021
First Submitted That Met QC Criteria
March 29, 2021
First Posted (Actual)
March 30, 2021
Study Record Updates
Last Update Posted (Actual)
September 18, 2023
Last Update Submitted That Met QC Criteria
September 15, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 29BRC20.0331
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
All collected data that underlie results in a publication
IPD Sharing Time Frame
Data will be available beginning two years and ending five years following the publication
IPD Sharing Access Criteria
Data access requests will be reviewed by the internal committee of Brest UH.
Requestors will be required to sign and complete a data access agreement.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hearing Loss, GJB2, Cis Regulation, DFNB1
-
Regeneron PharmaceuticalsWithdrawnCongenital Hearing Loss Secondary to Biallelic Mutations in the Otoferlin Gene (OTOF) | Biallelic Mutations in the Gap Junction Beta 2 (GJB2) Gene | Digenic Mutations in GJB2/Gap Junction Beta 6 (GJB6) GenesUnited States
-
SensorionRecruitingSensorineural Hearing Loss, Bilateral | Congenital Deafness | AUNB1 | DFNB1A | DFNB9 | OTOF Gene Mutation | GJB2 Gene MutationFrance